HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

(2018) Chloe Orkin et al.   Lancet HIV

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

(2017) Nicola Gianotti et al.   PLoS One

Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial

(2016) José R. Santos et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

(2016) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

(2016) PM Girard et al.   HIV MEDICINE

Trends in Darunavir Resistance-Associated Mutations and Phenotypic Resistance in Commercially Tested United States Clinical Samples Between 2006 and 2012

(2015) Erkki Lathouwers et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Efficacy of protease inhibitor monotherapyvs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials

(2015) JR Arribas et al.   HIV MEDICINE

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects

(2015) PJ Ruane et al.   HIV MEDICINE

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

(2015) Anthony Mills et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

(2015) Nicholas I Paton et al.   Lancet HIV

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

(2014) Karen Tashima et al.   AIDS Research and Therapy

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

(2013) Erkki Lathouwers et al.   ANTIVIRAL THERAPY

Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial

(2013) Giovanni Guaraldi et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Increase in Single-Tablet Regimen Use and Associated Improvements in Adherence-Related Outcomes in HIV-Infected Women

(2013) David B. Hanna et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

(2012) C Orkin et al.   HIV MEDICINE

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load

(2012) JR Arribas et al.   HIV MEDICINE

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

(2011) Pedro Cahn et al.   AIDS

Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials

(2008) Sandra de Meyer et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES